To date, stem cell transplantation has been the best curative treatment method for acute leukemia, for which T-cells are the faciliatators of the graft versus leukemia response. As explained here by Marion Subklewe, MD, of LMU-University Hospital Munich, Munich, Germany, it is thus very exciting that new T-cell engager constructs can now be used to independently and specifically harness these benefits. Dr Subklewe then gives us an overview of a Phase I US/EU trial investigating an anti-CD3/CD33 bispecific T-cell engaging antibody for relapsed/refractory acute myeloid leukemia (AML). This video was recorded at the 1st International Workshop on Acute Leukemias (iwAL), held in St. Pete Beach, FL.
Harnessing T-cells in acute leukemia and an anti-CD33/CD3 BiTE antibody
